Soma Nova turns raw genome into a defensible clinical result — diagnoses, drug-response guidance, and risk — with a qualified human signing off every call.
Every clinical assertion is evidence-linked and human-reviewed.
A single genome yields millions of variants and a handful that matter. Resolving them still depends on scarce specialists and manual curation that does not scale.
Sequencing is commoditising. Interpretation is the durable, defensible layer.
The Genomics Intelligence Platform is built as distinct layers — how it reasons, how it runs, and how it accumulates a lifelong model of the patient. Each is shown below.
Learned models are grounded by an explicit, curated knowledge graph. Reading top-down: copilots serve the clinician; every layer beneath exists to make the layer above defensible.
Stateless interpretation scales horizontally; a shared, stateful evidence substrate keeps every result consistent and reproducible years later.
The genome is fixed; its meaning is re-read as knowledge, phenotype and environment evolve. Nine data layers fuse into one lifelong asset.
Stable genetic baseline, reinterpretable over a lifetime.
Context for genotype–phenotype reasoning.
Drives phenotype-aware prioritisation.
Correlates structural with molecular signal.
Dynamic physiological state.
Modifiable risk factors.
Real-time monitoring and trends.
Gene–environment interaction.
Comparative and public-health inference.
No ungrounded output. Each call links to the criteria and citations behind it — auditable years later, not just today.
A criteria engine classifies, an LLM synthesises, and a named clinical reviewer stands behind every result.
Interoperability is the strategy. Reports drop into existing LIMS and EHR workflows without a translation layer.
Cloud-agnostic Kubernetes lets health systems and governments keep data inside their own borders.
From the germline to the whole population — each module built for the buyer who owns the decision.
Faster, more consistent diagnosis — shortening the diagnostic odyssey.
Explore →Somatic interpretation with TMB, MSI, HRD and therapy matching.
Explore →Pre-emptive dosing guidance at the point of prescription.
Explore →Carrier, prenatal NIPT interpretation and newborn screening.
Explore →Cohort-scale risk stratification and public-health analytics.
Explore →Longitudinal risk modelling across genomic, clinical and wearable data.
Explore →Permanent, familial and predictive — a breach affects relatives who never consented. Security is core architecture, engineered in from the start.
Native standards for genomic exchange and reporting.
Zero-trust, encryption everywhere, data kept in-region.
Transparent criteria engines, not opaque black boxes.
Immutable audit trail and versioned knowledge per case.
Anchor sites are partners, not customers. Commit a defined case volume and named reviewers; get early capability and a real say in the roadmap.
Rare disease · Oncology · Population — India & UK first.